Discontinuation of Continuation or Maintenance Electroconvulsive Therapy Caused by the COVID-19 Pandemic: A Naturalistic Study Investigating Relapse in Patients With Major Depressive Disorder. Issue 4 (17th December 2021)

• Record Type: Journal Article
• Authors: Van de Velde, Nele; Geerts, Pieter-Jan; Tandt, Hannelore; Vanderhasselt, Marie-Anne; Titeca, Koen; Lemmens, Gilbert
• Is Part Of: Journal of ECT. Volume 37:Issue 4(2021)
• Page Start: 230
• Page End: 237
• Publication Date: 2021-12-17
• Subjects: major depressive disorder -- continuation electroconvulsive therapy -- maintenance electroconvulsive therapy -- COVID-19; Electroconvulsive therapy -- Periodicals; Shock therapy -- Periodicals; Electroconvulsive Therapy -- Periodicals; Electroconvulsive therapy; Shock therapy; Periodicals; Periodicals; Electronic journals; 616.89122
• DOI: 10.1097/YCT.0000000000000785
• Languages: English
• ISSNs: 1095-0680

Abstract

Abstract : Background: Continuation or maintenance electroconvulsive therapy (C/M-ECT) is recommended to reduce relapse rates of patients with major depressive disorder. During the ongoing COVID-19 pandemic, ECT services have come under pressure or needed to close because of redirected resources and safety reasons. We investigated the impact of C/M-ECT discontinuation on relapse in patients with unipolar depressive disorder in Flanders, Belgium. Methods: Between March 30 and June 18, 2020, all patients receiving C/M-ECT in 2 ECT centers were included. Continuation or maintenance electroconvulsive therapy was discontinued in 33 patients and continued in 4 patients. Relapse was defined as the need to restart ECT or the need for hospitalization. Depressive symptoms were assessed every 3 weeks using the Patient Health Questionnaire, the Clinical Global Impression Scale, and 2 additional patient-rated questions. Results: Relapse in the discontinuation group was 60.6%. All 4 patients who continued ECT remained remitted. Kaplan-Meier survival analysis showed significantly shorter relapse rates for patients receiving bitemporal and/or frequent C/M-ECT (1- to 2-week intervals). Patients older than 60 years showed longer survival rates. Conclusions: Our results confirm earlier prospective and retrospective data regarding the efficacy and importance of C/M-ECT as relapse prevention. After treatment discontinuation, close monitoring of early warning signs for relapse is crucial, especially in the first few months. With the COVID-19 pandemic continuing, our data provide an indication of the necessity to ensure adequate care and access to ECT not only for the acutely ill but also for the vulnerable patients who are depending on C/M-ECT.